These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9391522)

  • 1. Human behaviour, cost-effectiveness analysis and research and development priorities: the case of a schistosomiasis vaccine.
    Evans DB; Guyatt HL
    Trop Med Int Health; 1997 Nov; 2(11):A47-54. PubMed ID: 9391522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How cost-effective would a vaccine be against schistosomiasis?
    CVI Forum; 1996 Aug; (12):14. PubMed ID: 12321483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
    Murray J; McFarland DA; Waldman RJ
    Bull World Health Organ; 1998; 76(4):343-52. PubMed ID: 9803585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children.
    Chotivitayatarakorn P; Chotivitayatarakorn P; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2010 Jan; 41(1):114-25. PubMed ID: 20578490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
    Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
    Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desirable characteristics of a schistosomiasis vaccine: some implications of a cost-effectiveness analysis.
    Guyatt HL; Evans D
    Acta Trop; 1995 Jun; 59(3):197-209. PubMed ID: 7572426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of a rotavirus immunization program for the United States.
    Smith JC; Haddix AC; Teutsch SM; Glass RI
    Pediatrics; 1995 Oct; 96(4 Pt 1):609-15. PubMed ID: 7567319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving control of African schistosomiasis: towards effective use of rapid diagnostic tests within an appropriate disease surveillance model.
    Stothard JR
    Trans R Soc Trop Med Hyg; 2009 Apr; 103(4):325-32. PubMed ID: 19171359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.